Trusted for more than 20 years, HEMASHIELD grafts are the most used, most studied vascular products available in the market today. More than 2 million HEMASHIELD grafts have been implanted ...

The MAQUET line of FUSION grafts Graft merges ePTFE with PET, creating a completely new concept for peripheral vascular procedures. It delivers the easy handling of ePTFE with the reduced suture ...

Cite this: Technology Insight: The Evolution of Tissue-Engineered Vascular Grafts--From Research to Clinical Practice - Medscape - Jul 01, 2007. The recent transition to clinical use by two ...

LeMaitre Vascular stock has fallen back from recent highs, but still is up just over 65% over the past 12 months. Read why I ...

Gore & Associates announced the recent CE Mark approval of a lower-profile Gore Viabahn VBX balloon expandable endoprosthes ...

NDAQ:HUMA) Humacyte Provides Update on Commercial Launch and Pricing of Symvess(TM) (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma ...

Moreover, long-term immunosuppression requirements after transplantation can limit the clinical use of transplants due to their adverse effects, including organ toxicity, infections, malignancies, ...

The global cardiovascular devices market, valued at US$ 72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3% ...

Humacyte (HUMA) announced an update of plans for the commercial launch of Symvess for extremity arterial injury. Humacyte is responding to ...

Medtronic will be the exclusive U.S. distributor of Contego Medical’s portfolio, which includes a carotid stent system and ...